PCOS and Type 2 Diabetes Risk: What You Need to Know

Why does PCOS increase diabetes risk?

Insulin resistance is central to the connection between PCOS and type 2 diabetes. In insulin resistance, cells throughout the body respond poorly to insulin, requiring the pancreas to produce more and more insulin to maintain normal blood sugar. Over time, the pancreas can no longer compensate, and blood sugar rises — first to prediabetes levels, then potentially to type 2 diabetes.

Insulin resistance in PCOS is not simply a consequence of weight gain — it is present in lean women with PCOS as well, suggesting it is a fundamental feature of the syndrome in many cases. Elevated insulin levels also drive androgen overproduction in the ovaries, creating a self-reinforcing cycle: PCOS worsens insulin resistance, and insulin resistance worsens PCOS.

The 2023 International Evidence-Based PCOS Guideline explicitly identifies cardiometabolic risk — including type 2 diabetes — as a primary long-term health concern requiring monitoring in all women with PCOS 1Ref 1Teede HJ, Tay CT, Laven JJE, Dokras A, et al. (2023).Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome.Cardiometabolic risk including diabetes as a primary long-term concern in PCOS; OGTT recommended for screening; lifestyle intervention for metabolic management.

How much higher is the risk?

The elevated diabetes risk in PCOS is clinically significant. The 2013 Endocrine Society clinical practice guideline for PCOS notes that women with PCOS have substantially higher rates of impaired glucose tolerance and type 2 diabetes compared with age-matched women without PCOS 2Ref 2Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, Welt CK (2013).Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline.Substantially higher rates of impaired glucose tolerance and type 2 diabetes in women with PCOS; metformin for insulin resistance.

This risk is present even in normal-weight women with PCOS, though it is amplified by overweight and obesity. Age also plays a role — the metabolic risk tends to increase over time, particularly around and after menopause when protective effects of certain hormones change.

Impaired glucose tolerance (prediabetes) appears to be particularly prevalent in PCOS — many women have significant insulin resistance well before any formal diabetes diagnosis.

How and when should blood sugar be screened in PCOS?

The 2023 PCOS international guideline recommends that all women with PCOS undergo assessment for diabetes risk and impaired glucose tolerance — ideally using an oral glucose tolerance test (OGTT) rather than fasting glucose or A1c alone, as the OGTT more reliably detects post-meal glucose abnormalities that may be the earliest sign of metabolic dysfunction in PCOS 1Ref 1Teede HJ, Tay CT, Laven JJE, Dokras A, et al. (2023).Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome.Cardiometabolic risk including diabetes as a primary long-term concern in PCOS; OGTT recommended for screening; lifestyle intervention for metabolic management.

The US Preventive Services Task Force recommends diabetes screening for overweight and obese adults beginning at age 35 3Ref 3US Preventive Services Task Force; Davidson KW, Barry MJ, Mangione CM, et al. (2021).Screening for Prediabetes and Type 2 Diabetes: US Preventive Services Task Force Recommendation Statement.USPSTF recommendation for diabetes screening starting at age 35 for overweight/obese adults, but for women with PCOS, earlier screening is appropriate regardless of weight because the underlying insulin resistance makes the risk relevant at younger ages.

If your initial screen is normal, guidelines generally suggest repeating it every one to three years given the ongoing risk — more frequently if you have additional risk factors such as a family history of diabetes, significant weight gain, or a prior gestational diabetes diagnosis.

What can reduce the risk of progression to diabetes?

The evidence base here is more robust than many people realize:

Lifestyle modification The landmark Diabetes Prevention Program trial demonstrated that structured lifestyle intervention — sustained modest weight loss through diet and increased physical activity — reduced progression from prediabetes to type 2 diabetes by over 50% 4Ref 4Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group (2002).Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.Lifestyle intervention reduces diabetes progression from prediabetes by over 50%; metformin also reduces risk though less effectively. While this trial was not specific to PCOS, women with PCOS-related insulin resistance stand to benefit similarly. The 2023 PCOS guideline places structured lifestyle intervention at the center of metabolic risk management 1Ref 1Teede HJ, Tay CT, Laven JJE, Dokras A, et al. (2023).Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome.Cardiometabolic risk including diabetes as a primary long-term concern in PCOS; OGTT recommended for screening; lifestyle intervention for metabolic management.

Weight-bearing and aerobic exercise improve insulin sensitivity in their own right, independent of weight loss — important for women with PCOS who find weight loss difficult.

Metformin Metformin is an insulin-sensitizing oral medication used in both diabetes and PCOS. In the Diabetes Prevention Program, metformin also reduced progression to diabetes, though less effectively than lifestyle intervention overall 4Ref 4Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group (2002).Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.Lifestyle intervention reduces diabetes progression from prediabetes by over 50%; metformin also reduces risk though less effectively. In PCOS specifically, metformin is used when lifestyle measures are insufficient or when insulin resistance is significant, and may be considered for women at high risk of diabetes progression 2Ref 2Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, Welt CK (2013).Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline.Substantially higher rates of impaired glucose tolerance and type 2 diabetes in women with PCOS; metformin for insulin resistance.

Managing weight For women with PCOS who are overweight, weight management provides substantial metabolic benefit — improving insulin resistance, lowering androgen levels, and reducing cardiometabolic risk. Even a modest reduction of 5 to 10% of body weight shows measurable metabolic improvement in clinical studies.

Does treating PCOS reduce diabetes risk?

Addressing the hormonal features of PCOS does not automatically eliminate metabolic risk, but it can contribute. Reducing androgen levels (through combined oral contraceptives or other approaches) may modestly improve insulin sensitivity. Metformin addresses both the PCOS hormonal picture and insulin resistance together.

However, no single PCOS treatment eliminates the underlying susceptibility to insulin resistance. Long-term monitoring and lifestyle strategies remain necessary regardless of what medical treatment you are on for PCOS symptoms.

Who should manage PCOS-related metabolic risk?

Your primary care clinician, OB-GYN, or endocrinologist can all perform metabolic screening. For women with PCOS who already have prediabetes or significant insulin resistance, a referral to an endocrinologist or a diabetes prevention program may be appropriate.

A Gale primary care clinician can order and interpret glucose screening, discuss lifestyle strategies, and help determine whether metformin or specialist referral is the right next step for your metabolic health.